Try a new search

Format these results:

Searched for:

person:lathaa01

in-biosketch:true

Total Results:

46


Risk of Metachronous Colorectal Cancer after Segmental or Extended Resection in Patients with Lynch Syndrome

Hill, Matthew B; Tawantanakorn, Thikhamporn; Gonen, Mithat; Abbass, Mohammad A; Shia, Jinru; Guillem, Jose G; Latham, Alicia; Garcia-Aguilar, Julio; Stadler, Zsofia K; Weiser, Martin R
BACKGROUND:The recommendation for patients with Lynch syndrome (LS) to undergo extended colectomy at colorectal cancer (CRC) diagnosis is increasingly controversial due to associated long-term morbidity, no benefit in overall survival, and recent advances in immunotherapy. STUDY DESIGN/METHODS:A prospective institutional database was queried for patients with LS diagnosed with CRC between 1969 and 2024, and rates of metachronous CRC and 10-year overall survival were analyzed. RESULTS:Metachronous CRC, with a median of 13 (interquartile range 5 to 20) years between diagnoses, occurred in 88 of 450 patients (20%): 83 of 350 patients (24%) who underwent segmental resection, 2 of 40 patients (5%) who underwent extended resection, and 3 of 60 patients (5%) who did not undergo surgery. Metachronous CRC was more common in patients with variants in high-risk ( MLH1 , MSH2 ) vs low-risk ( MSH6 , PMS2 ) genes: 80 of 326 patients (25%) vs 8 of 124 patients (6%) (p < 0.001). Extended resection was associated with a lower rate of metachronous CRC compared with segmental resection in patients with high-risk variants (2 [6%] of 34 vs 75 [30%] of 252; p = 0.006) but not in patients with low-risk variants (0 of 6 vs 8 [8%] of 98; p = 1.00). Ten-year overall survival was 90% (95% CI 86% to 93%) for the full cohort (median follow-up, 7.0 years), 89% (95% CI 85% to 93%) after segmental resection, and 96% (95% CI 88% to 100%) after extended resection. CONCLUSIONS:For CRC patients with variants in high-risk LS genes, extended resection can significantly reduce the risk of metachronous CRC but does not lengthen overall survival. Segmental resection with close endoscopic surveillance can be a reasonable alternative, given the opportunity for repeat surgery or immune checkpoint blockade.
PMID: 41773741
ISSN: 1879-1190
CID: 6068382

Subclinical Telomere Biology Disorder in Cancer Patients Heterozygous for the RTEL1 R1264H Founder Variant

Banaszak, Lauren G; Fiala, Elise; Ceyhan-Birsoy, Ozge; Khurram, Aliya; Kemel, Yelena M; Walsh, Michael F; Liu, Ying; Carlo, Maria; Latham, Alicia; Murciano-Goroff, Yonina R; Abbass, Mohammad Ali; Berger, Micheal; Petrini, John H J; Mandelker, Diana; Offit, Kenneth; Stadler, Zsofia Kinga
RTEL1 R1264H is a founder variant with a carrier frequency of 0.3%-1.0% in the Ashkenazi Jewish population. While biallelic RTEL1 R1264H causes a severe form of telomere biology disorder (TBD) presenting in childhood, the clinical significance of monoallelic carrier status has remained uncertain, limiting effective counseling and management. Here, we describe the clinical features, telomere lengths, and tumor somatic profiles of cancer patients found to be heterozygous for RTEL1 R1264H to evaluate for evidence of subclinical TBD in this population. Among 39,337 individuals who underwent RTEL1 germline analysis via MSK-IMPACT, 32 (0.08%) were incidentally found to be heterozygous for RTEL1 R1264H. Three individuals (9%) met diagnostic criteria for TBD based on compatible clinical features and telomere shortening, and two additional individuals (6%) had histories suspicious for TBD but did not have telomere length data available. Notably, 7 individuals (22%) experienced severe or fatal therapy-related toxicities, despite many lacking other clinical features of a TBD. These findings support that RTEL1 R1264H can act in an autosomal dominant fashion and confer TBD disease risk, albeit with low penetrance, and may increase susceptibility to treatment-related complications.
PMCID:13048689
PMID: 41424170
ISSN: 1552-4833
CID: 6068352

High frequency and unique subtypes of meningioma in patients with BAP1 tumor predisposition syndrome

Ramsey, Kaylee A; Byrne, Lindsey; Taylor, Olivia B; Soliman, Amr; Schreiner, Emma; Gray, Isabella; Latham, Alicia; Sheikh, Rania; Ahmadian, Saman S; Lonser, Russell R; Palmer, Joshua D; Carlo, Maria I; Cebulla, Colleen M; Abdel-Rahman, Mohamed H
PURPOSE: BAP1-tumor predisposition syndrome (BAP1-TPDS) is associated with four main cancers: uveal melanoma, cutaneous melanoma, malignant mesothelioma, and renal cell carcinoma. However, additional cancers are found more rarely in BAP1-TPDS patients. The aim of this study was to investigate the association, clinical, and pathologic characteristics of meningioma in BAP1-TPDS. METHODS: We conducted a retrospective chart review of meningiomas in two independent cohorts of patients with germline BAP1 pathogenic or likely pathogenic (P/LP) variants at The Ohio State University Wexner Medical Center and at the Memorial Sloan Kettering Cancer Center from October 1st, 2010 date to April 21st, 2025. Additionally, we conducted a literature review of meningioma case studies for individuals with germline BAP1 (P/LP) variants. RESULTS: In a cohort of 237 subjects with BAP1-TPDS, we identified 6.8% (16/237) with a history of meningiomas. The average age of diagnosis was 44.5 years (17–71). For patients with available pathology, 61.5% (8/13) of the tumors were grade 2/3. Patients with available tumor tissue 83.3% (5/6) showed evidence of BAP1 biallelic inactivation. Family history of meningioma was reported in 18.8% (3/16) of patients. Four cases of meningioma were identified during meningioma surveillance imaging, and five cases had recurrences after treatment. Published cases were consistent with the early age of onset, high-grade tumors, and clinical phenotype of tumors. CONCLUSION: This study provides additional evidence that high-grade brain and spinal meningiomas are part of the clinical spectrum of BAP1-TPDS. Craniospinal imaging surveillance in the BAP1-TPDS population should be considered starting around puberty, enabling early detection and management for individuals with BAP1-TPDS.
PMID: 41670784
ISSN: 1573-7373
CID: 6068372

Age-Related Germline Landscape of Endometrial Cancer: Focus on Early-Onset Cases

Wang, Judy J; Milani, Juliet; Kane, Sarah; Zhou, Qin; Iasonos, Alexia; Latham, Alicia; Kemel, Yelena; Carlo, Maria; Abbass, Mohammad; Banaszak, Lauren G; Kesserwan, Chimene; Murciano-Goroff, Yonina R; Mueller, Jennifer J; Abu-Rustum, Nadeem R; Makker, Vicky; Ellenson, Lora H; Berger, Michael F; Mandelker, Diana; Offit, Kenneth; Stadler, Zsofia; Aghajanian, Carol; Weigelt, Britta; Liu, Ying L
PURPOSE/OBJECTIVE:Early-onset endometrial cancer (eoEC) is increasing, and germline drivers may be enriched in younger patients. We sought to define germline pathogenic variants (gPVs) in those with EC by age. METHODS:We identified patients with EC who underwent clinical tumor-normal sequencing from December 2014 to June 2021 and collected clinical variables. Logistic regression models evaluated associations between age at EC diagnosis and presence of gPV, biallelic inactivation, and Lynch Syndrome (LS). Age categories were defined as early-onset (eoEC, EC < 50 years) and late-onset (EC ≥ 70 years) and were compared with those diagnosed ages 50-69 years. RESULTS:= .016). LS was enriched in eoEC, with 6.5% of patients diagnosed age <50 years having LS. In multivariable models compared with those with EC diagnosed age 50-69 years, eoEC was more likely to exhibit biallelic inactivation (odds ratio, 3.34 [95% CI, 1.44 to 7.35]) and be associated with LS (hazard ratio [HR], 3.49 [95% CI, 1.63 to 7.01]). Among early-onset EC, 14 (50%) of 28 gPV were high penetrance and 14 (50%) of 28 exhibited biallelic inactivation. However, heterogeneity was observed, and rates of gPV were 8.9% and 19%, biallelic inactivation was 0% and 11%, and LS was 2.2% and 8% in those diagnosed age <40 years and 40-49 years, respectively. CONCLUSION/CONCLUSIONS:Rates of gPV, biallelic inactivation, and LS differ across age groups for EC, with high-penetrant genes driving tumorigenesis enriched in younger patients. However, very-early-onset EC may have different drivers and necessitates more research.
PMCID:12857754
PMID: 41610375
ISSN: 2473-4284
CID: 6068362

Defining the Histopathological, Clinical, and Genetic Characteristics of Familial BAP1-associated Renal Cell Carcinoma [Letter]

Posada Calderon, Lina; Dawidek, Mark T; Tang, Cerise; Kim, Minsoo; Zong, Grace; Bandlamudi, Chai; Mehine, Miika; Sheikh, Rania; Kemel, Yelena; Eismann, Lennert; Ganz, Marc; Barbakoff, Daniel; Byrne, Lindsey; Gray, Isabella; Nethala, Daniel; Rathi, Nityam; Vocke, Cathy D; Liu, Ying L; Latham, Alicia; Stadler, Zsofia K; Offit, Kenneth; Coleman, Jonathan A; Goh, Alvin C; Russo, Paul; Reznik, Ed; Motzer, Robert J; Chen, Ying-Bei; Linehan, W Marston; Reuter, Victor E; Abdel-Rahman, Mohammed H; Ball, Mark W; Hakimi, A Ari; Carlo, Maria I
PMCID:12851415
PMID: 40925749
ISSN: 1873-7560
CID: 6068342

Neoplasia Detection Through Colonic Surveillance Among Young Individuals With MSH6 / PMS2 -Associated Lynch Syndrome

Latham, Alicia; Liu, Ying L; Constantino, Gillain; Borio, Matilde; McCoy, Sean; Dudzik, Christina; Heiman, Jordan; Kemel, Yelena; Ukaegbu, Chinedu; Carlo, Maria I; Ranganathan, Megha; Kane, Sarah; Long, Jessica M; Syngal, Sapna; Markowitz, Arnold J; Stadler, Zsofia K; Yurgelun, Matthew B; Katona, Bryson W
INTRODUCTION/BACKGROUND:The age to initiate colonoscopy in MSH6 / PMS2 -associated Lynch syndrome (LS) remains uncertain. In this study, we characterize colonoscopy findings among young individuals with MSH6 / PMS2 -associated LS. METHODS:Retrospective review of a multi-institutional cohort of individuals with MSH6/PMS2 -associated LS undergoing colonoscopy before the age of 50 years was performed. Neoplastic lesions were defined as colorectal cancer (CRC), adenomas, or nonhyperplastic serrated lesions. RESULTS:Among 285 individuals (161 [56%] MSH6 ; 124 [44%] PMS2 ), 125 (44%) had a neoplastic finding inclusive of 53 (19%) with CRC (32 [20%] MSH6 ; 21 [17%] PMS2 ), with median age at CRC diagnosis of 38 years and 38% reporting CRC family history. Among 824 available pooled procedures, there were 194 procedures (24%) with neoplastic lesions identified, including 21 (2.6%) with advanced adenomas, 5 (0.5%) with advanced serrated lesions, and 34 (4.1%) with CRC. Among 122 procedures performed under the age of 30 years, 16 (13%) had neoplastic findings and 4 (3.3%) had CRC, of which all were found before LS diagnosis. Findings did not differ between MSH6 and PMS2 carriers. DISCUSSION/CONCLUSIONS:Among individuals with MSH6/PMS2 -associated LS undergoing early colonoscopy, neoplasia was common, even in those aged younger than 30 years. Current recommendations suggesting delayed initiation of surveillance among such patients may lead to missed preventive opportunities.
PMID: 40013688
ISSN: 1572-0241
CID: 6068302

Germline landscape of high grade serous ovarian cancer across age groups: Is age just a number?

Sia, Tiffany Y; Moufarrij, Sara; Milani, Juliet; Kane, Sarah; Zhou, Qin; Fong, Christopher; Khurram, Aliya; Kemel, Yelena M; Sheehan, Margaret; Latham, Alicia; Carlo, Maria I; Murciano-Goroff, Yonina R; Banaszak, Lauren G; Abbass, Mohammad; Offit, Kenneth; Iasonos, Alexia; Roche, Kara Long; Chi, Dennis S; Mandelker, Diana; Aghajanian, Carol; Abu-Rustum, Nadeem R; Stadler, Zsofia Kinga; Tew, William P; Lichtman, Stuart M; Liu, Ying L
OBJECTIVE:To characterize age-related variations in germline pathogenic variants (gPVs) in patients with high-grade serous ovarian cancer (HGSOC). METHODS:Patients with HGSOC who underwent clinical tumor-normal sequencing of ≥76 genes from 1/1/2015-11/15/2022, were included. Clinical variables including age at diagnosis were collected. Logistic regression models were built to examine associations between gPV, age, and clinical variables. RESULTS:Of 1231 patients, median age at diagnosis was 63 years (range, 33-93); 163 patients (13 %) were diagnosed at age ≤ 49, 739 (60 %) between ages 50-69, and 329 (27 %) at age ≥ 70 years. gPVs were observed in 68 (42 %), 200 (27 %), and 52 patients (16 %) respectively, p < 0.001. Compared to patients diagnosed between ages 50-69, those diagnosed at age ≥ 70 were less likely to have a gPV (OR: 0.58; 95 % CI: 0.38-0.86) and those diagnosed at age ≤ 49 were more likely to have a gPV (OR: 1.78; 95 % CI: 1.18-2.68), after adjustment for genetic ancestry and NCI Comorbidity Index. Seven of 67 patients (10 %) diagnosed at age ≥ 80 years had a gPV, including 2 in OC-related genes (BRCA2, PALB2). Twelve of 21 patients (57 %) diagnosed at age ≤ 39 years had a gPV, all in OC-related genes. No differences in genetics follow-up or poly (ADP-ribose) polymerase inhibitor use were observed by age (p > 0.05). CONCLUSION:Although gPV rates varied by age with the highest rates observed in patients with early-onset OC, rates were high (≥10 %) in all age groups, with similar genetics follow-up and implementation of targeted therapies. Universal genetic testing is important for all patients with OC regardless of age.
PMCID:12418476
PMID: 40812120
ISSN: 1095-6859
CID: 6068332

Strategic Plan of the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer (CGA-IGC): A practical roadmap to move the hereditary gastrointestinal cancer field forward [Editorial]

Katona, Bryson W; Stanich, Peter P; Chittenden, Anu; Hall, Michael J; Idos, Gregory E; Koptiuch, Cathryn; Latham, Alicia; Pearlman, Rachel; Singh, Aparajita; Levinson, Elana; Dudley, Beth
The Collaborative Group of the Americas on Inherited Gastrointestinal Cancer (CGA-IGC) is an organization of healthcare providers, researchers, and advocates whose mission is to be a leading global authority in advancing the science and clinical management of hereditary gastrointestinal cancer syndromes. In 2024, the Executive Council developed a Strategic Plan, outlined here, to guide the organization's work over the next 3 years. The Strategic Plan is based on the four pillars of Education, Discovery & Innovation, Community & Collaboration, and Organizational Vitality, with associated goals, action plans, and metrics for each pillar. Ultimately, the Strategic Plan will help CGA-IGC fulfill its vision and mission to advance the science and clinical management of hereditary gastrointestinal cancers.
PMID: 40451961
ISSN: 1573-7292
CID: 6068322

Germline pathogenic variants in DNA repair pathways: a key feature in a significant subset of translocation-associated sarcomas

Saoud, Carla; Dermawan, Josephine K; Arora, Kanika; Tap, William D; Reed, Damon; Slotkin, Emily K; Wexler, Leonard H; Murciano-Goroff, Yonina R; Latham, Alicia; Mandelker, Diana L; Antonescu, Cristina R
Translocation-associated sarcomas (TAS) are rare, phenotypically heterogeneous, with predisposition for young adults. We aimed to investigate the clinical impact of germline pathogenic/likely pathogenic (P/LP) variants in a diverse group of TAS and to conduct a comprehensive comparative analysis of clinicopathologic features, genomic alterations, and survival outcomes. A retrospective cohort of 426 TAS patients with both tumor and germline DNA sequencing was investigated for clinical actionability of P/LP variants, and potential impact on current screening guidelines and clinical interventions. Twenty-eight patients (6.6%) carried Tier 1 germline P/LP variants (moderate to high penetrance autosomal dominant (AD) variants), while 27 (6.3%) patients carried Tier 2 variants (monoallelic autosomal recessive or low penetrance AD variants). Compared to Tier 2, Tier 1 patients were more commonly of European ancestry and had a higher frequency of first- and second-degree relatives with cancer history. Notably, the frequency of both tiers variants was lower among pediatric patients compared to older patients and differed across TAS histologies, with the highest observed in solitary fibrous tumors. All germline P/LP variants were monoallelic, dispersed across multiple genes, and enriched in DNA damage repair pathways. There was no association between the germline P/LP variants and somatic genomic profile, nor any survival impact when stratified by histotype. Our findings highlight the incidence of clinically significant germline P/LP variants in TAS is lower in pediatric patients, questioning current sarcoma genetic screening guidelines and supporting germline testing for all TAS patients. Significant interventions were triggered in 46% of Tier 1 (n = 13), including platinum-based chemotherapy and PARP inhibitors in two BRCA1/2 patients.
PMCID:12059086
PMID: 40335592
ISSN: 2397-768x
CID: 6068312

Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer

O'Connor, Catherine A; Harrold, Emily; Lin, David; Walch, Henry; Gazzo, Andrea; Ranganathan, Megha; Kane, Sarah; Keane, Fergus; Schoenfeld, Joshua; Moss, Drew; Thurtle-Schmidt, Deborah M; Suehnholz, Sarah P; Chakravarty, Debyani; Balogun, Fiyinfolu; Varghese, Anna; Yu, Kenneth; Kelsen, David; Latham, Alicia; Weigelt, Britta; Park, Wungki; Stadler, Zsofia; O'Reilly, Eileen M
IMPORTANCE:Microsatellite (MS) instability (MSI-H) occurs frequently in Lynch syndrome (LS)-associated tumors and is associated with response to immune checkpoint blockade (ICB) therapy. MSI-H is conferred by germline or somatic variants in mismatch repair genes. The contribution of somatic oncogenesis to MSI-H in pancreatic cancer (PC) is unknown. OBJECTIVE:To evaluate an LS-related PC cohort to define clinicogenomic features, describe somatic MSI-H cases (germline negative), characterize response to ICB, and guide preferred MS testing methods. DESIGN, SETTING, AND PARTICIPANTS:This single-institution, retrospective analysis was conducted from March 2012 to July 2023 at Memorial Sloan Kettering Cancer Center and included 55 patients with PC and either an LS germline pathogenic variant (gPV) or somatic mismatch repair (MMR) variant. MAIN OUTCOMES AND MEASURES:Composite MMR and MS status determined using orthogonal methods. An artificial intelligence classifier was used to account for low-cellularity specimens. Demographic and clinical data were abstracted from medical record. Zygosity status and somatic comutation landscape analyzed. RESULTS:Fifty-five patients (23 women [42%]) had PC and an MMR variant: 32 (58%) had LS (LS cohort) and 23 (42%) had a somatic MMR variant (no germline pathogenic variant, somatic MMR cohort). In the LS cohort, 10 (31%) had gMSH2, 9 (28%) gMSH6, 8 (25%) gPMS2, 4 (13%) gMLH1, 1 (3%) gEPCAM. The median age at diagnosis was 68 years (range, 45-88 years). For composite MS status, 17 (59%) were MSI-H, 12 (41%) MS stable, and 3 MS unknown. Five cases were reclassified as MSI-H by the artificial intelligence classifier. In the somatic MMR cohort, 11 (48%) had MSH6, 7 (30%) MLH1, 3 (13%) MSH2, and 2 (9%) PMS2. The median age at diagnosis was 72 years (range, 66-85 years). For composite MS status, 10 (43%) were MSI-H, 11 (48%) MS stable, and 2 (9%) MS indeterminate. Six cases were reclassified as MSI-H by the artificial intelligence classifier. For the LS and somatic MMR cohorts, 20 received ICB (n = 17 MSI-H). The median ICB duration was 27.7 months (95% CI, 11.5 to not reached); the disease control rate was 80%. CONCLUSION:The results of this cross-sectional study suggest that MSI-H occurs due to LS or somatic oncogenesis in PC. Orthogonal MS testing is key in PC; the artificial intelligence classifier reclassified approximately 20% of cases, most of which were low cellularity. ICB for patients with LS or somatic MSI-H PC provided significant benefit.
PMCID:11378065
PMID: 39235819
ISSN: 2374-2445
CID: 6068292